Theodore Roosevelt is known for his time in Washington as president, for his governorship in New York, for leading the Rough ...

Top trio explain the shift from exploring the mystery of the town to confronting the consequences of seeking answers.

California's nonpartisan Top-Two was designed to give every voter a chance to participate in a meaningful primary and general ...

Kevin Warsh boiled down his advice for the Federal Reserve before an audience of investors last year. “Stop talking so much,” he said. “More thinking, less talking.” For more than a decade, Warsh has ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Fulcrum Therapeutics will lay off the majority of its workforce after it said it would terminate the development of a sickle-cell-disease treatment. The company on Thursday said it expects to reduce ...

With few treatments available for sickle cell disease, encouraging early clinical data for a Fulcrum Therapeutics drug made it one to watch. But another medicine from the same drug class was recently ...

Fulcrum Therapeutics (FULC) lost nearly 50% of its value in extended trading after the company disclosed plans to discontinue the development of its lead asset, pociredir, for sickle cell disease in ...

The oral drug, pociredir, was being tested to treat sickle-cell disease, an inherited blood disorder that can trigger pain, anemia and organ damage and reduce life expectancy. Sign up here. Pociredir ...

Fulcrum Therapeutics has scrapped its sole clinical-stage program after the FDA took a hard line on the modality following the recent withdrawal of Ipsen’s Tazverik from the U.S. market. Ipsen ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

June 1 (Reuters) - Fulcrum Therapeutics (FULC.O), opens new tab said on Monday it would stop developing its experimental sickle-cell disease drug after the U.S. Food and Drug Administration raised ...